Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · FATE THERAPEUTICS INC (FATE)

Fate Therapeutics receives $15 million CIRM grant to support FT819 lupus trial

Positive Impact 3 of 5 financing Written later

Fate Therapeutics said the California Institute for Regenerative Medicine awarded it a $15.0 million grant through its CLIN2 program to support the Phase 2 RECLAIM-LN trial of FT819 in lupus nephritis. The filing does not state financial results or any change to company guidance, so the grant's direct effect on shareholders is not quantified.

Key points

  • CIRM awarded a $15.0 million grant on September 25, 2026, under its CLIN2 program.
  • The grant supports the Phase 2 RECLAIM-LN trial of FT819 in refractory lupus nephritis.
  • The trial is expected to enroll approximately 53 patients; the primary endpoint is complete renal response at Week 26.

The filing

CompanyFATE THERAPEUTICS INC (FATE)
Form8-K, current report
Filed with the SECSep 28, 2026, 8:10 AM ET
Accession number0001193125-26-403429

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 28, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.